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107non to accurately measuremyocardial ECV consists of achievement of a
steady-state equilibrium of gadolinium-based contrast agent between
plasma and the cardiac interstitium. Currently, this requires a rather
complicated and time-consuming protocol, which hinders the large-
scale clinical application of this technique. In a recent issue of iJACC,
White et al. (1) wrote a seminal paper validating a bolus-only (pseudo-
equilibrium) technique to estimate the ECV in a wide range of cardiac
diseases, with different degrees of extracellular matrix expansion, by
comparing it against both a previously validated equilibrium (infusion)
technique and histology. In particular, they demonstrated that a
pseudo-equilibrium protocol (15 min after a 0.1 mmol/kg gadolinium
bolus) yielded ECV estimates comparable to those obtained with the
equilibrium protocol (0.1 mmol/kg bolus þ 0.011 mmol/kg/min
gadolinium infusion), even though the former overestimated myocar-
dial ECV in case of an important expansion of cardiac interstitium (i.e.,
ECV >0.4, as in the case of amyloid deposition or ﬁbrotic scars).
Moreover, both techniques showed very tight correlation with the
histologically determined collagen volume fraction.
Overall, the paper byWhite et al. (1) paves the way for clinical studies
on cardiac interstitium remodeling and for further methodological
studies exploring gadolinium contrast kinetics with particular regard to
diseases with extreme ECV expansion. In previous work, Flett et al. (2)
provided evidence on how the equilibrium can be reached with a
constant gadolinium infusion (0.1 mmol/kg þ 0.0011 mmol/kg/min
gadolinium) in patients with aortic stenosis or hypertrophic cardio-
myopathy. They acquired T1 values every 5 min and demonstrated that
the ECV remained constant over time and correlated with histology.
Another group (3) validated a different pseudo-equilibrium technique
(12 to 50 min after 0.2 mmol/kg gadolinium bolus) against a different
equilibrium technique (0.1 mmol/kg bolus þ 0.0017 mmol/kg/min
gadolinium infusion) in healthy volunteers, again by acquiringT1 values
every 5 min and demonstrating that ECV remained constant.
Conversely, little is known about gadolinium kinetics in cardiac
amyloidosis, which is characterized by marked interstitial expansion and
fast gadolinium accumulation but also very rapid gadolinium washout
from both the myocardium and the blood pool (4). In the current paper
(1), T1 acquisitions were performed only 15 min after bolus and during
infusion, with no serial T1 acquisitions to demonstrate a blood–
myocardium steady-state equilibrium. Moreover, the histological vali-
dation provided by the authors was limited to patients with aortic ste-
nosis undergoing valve replacement or patients with hypertrophic
cardiomyopathy undergoing septal myectomy (1,2). Histological vali-
dation of equilibrium or pseudo-equilibrium techniques is still lacking
for cardiac disease with ECV >0.4, such as in cardiac amyloidosis, in
which interstitial remodeling may be ascribed to disparate mechanisms
(including myocyte necrosis, amyloid deposition, and scarring).
Finally, we agree with the authors (1) that further technical devel-
opment is required before a bolus-only protocol for ECVmeasurement
becomes clinically available. This protocol should account for all
potentially relevant parameters (contrast delivery rate, dose, agent, and
acquisition timing) and be validated for diverse cardiac pathologies.
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REPLY : Myocardial Extracellular Volume
Measurement by Cardiac Magnetic Resonance
We thank Dr. Barison and colleagues for their interest in our
paper (1). Extracellular volume fraction (ECV) has promise as an
important future imaging biomarker but can be measured by a
number of different T1 mapping techniques (2,3). The primary
aim of our study was to support the concept that a sufﬁcient
dynamic (or “pseudo”) equilibrium exists with delay after a bolus
of contrast, such that an infusion-maintained steady state is not
necessary (1). By removing the need for this cumbersome, time-
consuming intervention (4), this method would expand the
clinical applicability of ECV quantiﬁcation into routine study.
We conﬁrmed that this approach is valid in the majority of
clinical patients who might be encountered in a clinic, but perhaps
not all.
The development of new imaging biomarkers requires multifac-
eted technical development, including correlation or “calibration”
with histology, clinical correlates (e.g., left atrial size), and hard
clinical outcomes. As Dr. Barison and colleagues rightly stress, no
histological correlations are yet available in “high ECV” diseases, in
particular, cardiac amyloidosis. Hopefully, this is within sight, but
histological quantiﬁcation has thus far proved challenging because
tissue stains have not adequately separated myocytes from amyloid
protein and ﬁbrosis.
Other methods, however, may be helpful. Dr. Barison and
colleagues point out that contrast behavior is abnormal in other
ways in amyloid. The behavior of contrast may reﬂect myocardial
wash-in/wash-out kinetics and total potential accumulation (vol-
ume of distribution), but other factors are at play. The decay curve
of gadolinium-diethylenetriaminepentaacetic acid in the blood is
multiexponential: ﬁrst dominated by redistribution in blood, then
by distribution with slow and fast exchange compartments in the
body, and later by renal elimination. These factors may be altered
in AL and ATTR amyloidosis. In AL amyloidosis in particular,
there may be large accumulations (in kilograms) of amyloid
deposits in the liver, spleen, tongue, and other soft tissues of the
body. Scrutiny of contrast behavior may therefore provide addi-
tional insights.
What is the correct ECV in amyloidosis? We found that the
ECV measured using the bolus-only method was consistently
higher than that determined by using the infusion method.
Although the infusion technique is theoretically superior, our global
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108understanding of amyloid contrast kinetic behavior remains limited,
for the reasons already discussed. However, a more pertinent
question for T1 mapping and the ﬁeld in general is this: is it the
“true” T1/ECV that is important or should one select the test that is
most reliable, is easy to apply, best permits the detection of early
disease and subtypes (5), tracks disease progression, and aids the
guidance of therapy? Exciting times lie ahead.
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